News Headlines Article

Supreme Court slates generic drug ‘pay-for-delay’ case
Modern Healthcare

The U.S. Supreme Court has agreed to hear arguments in a “pay-for-delay” case that has the Federal Trade Commission accusing generic drugmakers of violating competition laws by agreeing to accept $42 million in annual payments in exchange for not selling generic versions of a more-expensive brand-name testosterone gel. The FTC says the companies—lead respondent Watson Pharmaceuticals, along with Paddock Laboratories, Par Pharmaceutical Cos. and Abbott Laboratories subsidiary Solvay Pharmaceuticals—conspired illegally to keep cheaper drugs off the market, to the detriment of consumers of the brand-name drug.

Commands